Heterogeneous Tau Oligomers as Molecular Targets for Alzheimer’s Disease and Related Tauopathies

Chih Hung Lo

Lee Kong Chian School of Medicine, Nanyang Technological University, Singapore 308232, Singapore; chihhung.lo@ntu.edu.sg

Abstract: Tauopathies, including Alzheimer’s disease (AD), are a group of neurodegenerative disorders characterized by pathological aggregation of microtubule binding protein tau. The presence of tau neurofibrillary tangles, which are insoluble β-sheet fibrils, in the brain has been the histopathological hallmark of these diseases as their level correlates with the degree of cognitive impairment. However, recent studies suggest that tau oligomers, which are soluble proteins that are formed prior to insoluble fibrils, are the principal toxic species impairing neurons and inducing neurodegeneration. Targeting toxic tau oligomers is challenging, as they are mostly unstructured and adopting multiple conformations. The heterogeneity of tau oligomers is further illustrated by the different oligomeric species formed by various methods. The current models and technologies to study tau oligomerization represent important resources and avenues to push the forefront of elucidating the true toxic tau species. In this review, we will summarize the distinct tau oligomers generated using different strategies and discuss their conformational characteristics, neurotoxicity, relevance to pathological phenotypes, as well as their applications in drug discovery. This information will provide insights to understanding heterogeneous tau oligomers and their role as molecular targets for AD and related tauopathies.

Keywords: tau oligomers and aggregates; cellular and pathological heterogeneity; neurotoxicity; conformational ensembles; protein-protein interaction; molecular diversity; drug discovery; small molecules; biosensor; neurodegenerative diseases

1. Introduction

Alzheimer’s disease (AD) and related dementia are the top 7th leading causes of death in the world, afflicting more than 50 million people [1]. AD is a neurodegenerative disease and an example of tauopathies with a marked increase in the number of tau inclusions such as paired helical filaments (PHFs) and neurofibrillary tangles (NFTs) in affected brain regions of patients [2]. Tau is an intrinsically disordered protein, and its normal function is to regulate microtubule stability and axonal transport [3]. Under pathological conditions, the detachment of tau from microtubules results in misfolding and accumulation in the cytosol [4] which initiates the fibrillogenesis cascade including the formation of tau oligomers and the subsequent nucleation into PHFs and NFTs (Figure 1A) [5]. While NFTs have been the histopathological hallmark of AD and tauopathies [6], recent studies suggest that these large insoluble fibrils are not the primary toxic species and soluble tau oligomers may instead be the principal toxic tau species [7–10]. Studies, both in vitro and in vivo, have reported that tau oligomers promote neurotoxicity, and may be attributed to neurodegeneration and cognitive phenotypes in mice [11–16]. It has also been reported that promoting the growth of inert tau fibrils may be neuroprotective by sequestering toxic tau oligomers (Figure 1B) [17,18]. Furthermore, it has been suggested that tau oligomers may act as seeds that propagate between cells to induce misfolding of tau monomers and spreading of toxic tau species [19–21]. As a result, there is a shift of therapeutic paradigm from targeting large fibrillar aggregates to inhibiting or remodeling the formation of toxic soluble tau oligomers [22–25].
Figure 1. Tau oligomerization and fibrillization in Alzheimer’s disease and related tauopathies. (A) Misfolded tau monomers spontaneously form into both non-toxic and toxic soluble tau oligomers which subsequently fibrillize into insoluble paired helical filaments (PHFs) and neurofibrillary tangles (NFTs). (B) Insoluble species have been proposed to potentially have neuroprotective effect by sequestering toxic oligomers. (C) Aggregation inducers, cross-seeding, and the presence of tau repeat domain or cleaved species can facilitate the transition from non-toxic to toxic oligomers. (D) Small molecules that remodel tau oligomeric conformations or inhibit tau-tau interactions can promote the conversion of toxic to non-toxic oligomers and reduce neurotoxicity. Schematics are created with BioRender.com accessed on 10 October 2022.

Currently, there are no known effective disease modifying therapies targeting AD and tauopathies [26]. Among the >100 disease-modifying therapies currently in clinical developments, there are only a limited number of them (~10%) that are tau-focused [27]. The heterogeneity of toxic tau species has been attributed to the failure of clinical trials and impeded the discovery of effective therapeutics. Importantly, small molecules such as methylene blue, which are known to target tau fibrils, have failed to obtain desirable results in the clinical trials, potentially due to the conversion of tau fibrils into toxic tau oligomers [28,29]. While the focus has shifted from targeting insoluble NFTs to soluble oligomers, the heterogeneity of toxic tau oligomers, both in vitro and in vivo, remains to be resolved. The clinical heterogeneity has been reflected through the various types of toxic tau oligomers identified and isolated in different studies [30–36]. Other sources of tau heterogeneity lie in molecular variations such as spontaneous formation, seeding competency, expression levels, isoform composition, truncation, use of inducers, and post-translational modifications [37–42]. Hence, there is a need to understand the different types of tau oligomers formed as well as their detailed characterizations and functions.

Tau oligomers exist as an ensemble of distinct assemblies [43–47] which include both toxic and non-toxic, on- and off-pathway species along the fibrillogenesis cascade [17,25,48–52]. Capturing this complexity in an in vitro setting is extremely difficult and established protocols for obtaining tau aggregates from purified tau proteins have, not surprisingly, been shown to produce different tau assemblies depending on aggregation conditions [31,33,53,54]. Although no specific toxic tau species has been identified to date [55,56], several studies making use of purified recombinant proteins are able to produce stable toxic tau oligomers that can be used to study their role in AD pathology. These aggregation strategies include cross-seeding approaches as well as the use of inducers and cleaved species (Figure 1C). In addition, cell-based strategies have been adopted to model tau oligomerization and the associated neurotoxicity [52]. While the cellular system has the advantage of being physiologically relevant as well as containing the cellular components such as numerous chaperone proteins [57], caspases [58], and kinases [59] that play key roles in tau oligomerization [60], it is difficult to capture the biophysical characterizations as well as direct toxicity effect of specific toxic tau oligomers in cells because they are in an ensemble of conformations [41,42]. Several rational drug discovery efforts using purified recombinant protein and cell-based assays to discover small molecules that target toxic tau oligomers have yielded efficacious, cytoprotective compounds (Figure 1D) [61–67], and some have
further been shown to be neuroprotective in vivo [68,69]. However, there is currently no clinical trial conducted on targeting tau oligomers and it is imperative to advance successful pre-clinical studies into human trials [70–72].

In this review, we will describe the diverse types of tau oligomers with different conformations generated by various methods. We will also discuss the hypothesized functions and associated neurotoxicity of these tau oligomers, as well as their relevance to pathological phenotypes and applications in drug discovery. We conclude by providing future perspectives on identifying the true toxic tau species as well as delineating the mechanisms of pathogenic formation of heterogeneous tau oligomers and their role as molecular targets and potential biomarkers for AD and related tauopathies.

2. Spontaneous Formation of Tau Oligomers

Full-length wild-type (WT) tau proteins are known to be less prone to fibrillization, although excessive accumulation of these proteins can be toxic and are associated with sporadic AD [73,74]. Full-length WT tau has been shown to spontaneously form tau oligomers, rather than large fibrillar aggregates. An initial study used WT 2N4R purified tau proteins and concentrated them to create a mixture of tau monomers and granular oligomers, and the enriched granules generated β-sheet fibrils, suggesting that granular tau oligomers may be an intermediate form of tau filaments [30]. Importantly, these granular tau oligomers can be purified using sucrose step gradient centrifugation to separate from monomers and fibrils [30,75]. Although no functional or toxicity characterizations of these purified granular tau oligomers have been performed, purification of granular tau aggregates from human brains of different Braak stages suggests that granular tau aggregation precedes fibril formation [30]. These studies have proposed that tau aggregation initiates with the formation of soluble tau oligomers through disulfide binding and these oligomers would then convert into β-sheet granular tau oligomers which further interact and undergo fibrillization [30,75]. It would also be important to elucidate the initiation of the granular tau aggregation process in different brain regions to enhance the understanding of disease pathogenesis.

Another study used 1N4R and 2N4R recombinant human tau to generate monomeric, dimeric, and trimeric fractions of each isoform. The composition and height distribution of each fraction was verified by chromatography and atomic force microscopy. The toxicity of each fraction toward both human neuroblastoma cells and cholinergic-like neurons was assessed. Disulfide mediated trimeric oligomers of both splice variants, but not monomeric or dimeric species, displayed neurotoxicity at low nanomolar concentrations [36]. Interestingly, disulfide mediated oligomers have been shown to act through a nucleation effect, rather than the action of specific tau kinases, to initiate tau aggregation in mice [76]. In a separate study, an analysis of the oligomers formed by the six tau isoforms to study primary-quaternary structure relationship of tau has illustrated that 3R isoforms are more prone to oligomerization than the 4R isoforms [77].

The spontaneous formation of tau oligomers has also been demonstrated in both 2N4R WT tau and mutant tau transfected cells. Cellular biosensors with spectroscopy probes have been used to detect the presence of tau oligomers through fluorescence resonance energy transfer (FRET), split fluorescent protein complementation (BiFC), and split luciferase complementation (SLC) assays [78]. Specifically, we have previously reported that 2N4R WT and mutant tau form oligomers in HEK293 cells as detect by FRET, but not β-sheet fibrillar species as shown by negative thioflavin-S (ThS) staining [52]. Even though both WT and mutant tau spontaneously form oligomers, there is a diverse view on their effect on cell death [73]. While some studies have suggested that WT tau is toxic to cells [79,80], several other studies have reported that WT tau overexpression does not induce cell death, despite the formation of oligomers and tau hyperphosphorylation [52,81–83]. On the other hand, mutant tau has a higher oligomerization propensity than WT tau [52] and is neurotoxic in both cellular and animal models of tauopathies [52,81,84]. For therapeutic targeting, we have conducted a FRET-based high-throughput screening (HTS) and identified MK-886 as
a small molecule that inhibits tau oligomerization and rescues P301L mutant tau induced cell death at nanomolar concentration [52]. This FRET based HTS strategy has also been used to discover effective small molecule inhibitors targeting alpha-synuclein oligomerization [85] and huntingtin exon 1 aggregation [86] and could be generally applicable to most intrinsically disordered proteins.

3. Heparin-Induced Tau Oligomerization

Heparin has been adopted by multiple studies to induce tau oligomerization. It has also been shown that heparin induces transition from inert monomers to seed-competent monomers to initiate the aggregation cascade [37,46] and remodels tau repeat domain (tauRD) towards fibrillization prone conformations [87]. We note here that the use of heparin to induce oligomers may result in the formation of both β-sheet and non-β-sheet oligomers and it is imperative to differentiate these two types of tau oligomers, such as through thioflavin-T (ThT) staining as they represent two distinct tau species [31,88,89].

Similar to spontaneously formed disulfide mediated oligomers, heparin-induced aggregation of recombinant tau forms two distinct dimers, cysteine-dependent and cysteine-independent, that resist reduction to different extents [90,91]. These distinct types of dimeric assembly were also observed in 2N4R WT tau expressing COS-7 cells, which were abolished with a PHF6 hexapeptide deletion at residues 306–311 and C291A/C322A mutations [90]. These results suggest that the formation of higher-order oligomers could be due to PHF6 hexapeptide promoting tau oligomerization through intermolecular disulfide crosslinking both in vitro [90] and in vivo [92]. Concurrent intermolecular bridging of microtubule-binding domain through cysteine-independent mechanism may further promote tau aggregation [90]. Furthermore, oligomeric assembly containing up to six to eight tau molecules is suggested to be necessary for the detection of β-sheet structure with ThT. Importantly, disulfide-bridge formation between tau and cell membranes has been shown to facilitate tau secretion [93].

In order to target disulfide mediated tau oligomers, a rosamine derivative with tau selective thiol reactivity inhibited oligomerization and the subsequent fibrillization cascades [94]. Furthermore, compounds containing 1,2-dihydroxybenzene such as DL-isoproterenol which penetrates the brain are capable of binding to tau and capping the cysteine residues of tau to prevent tau aggregation and rescue neuronal loss in mouse models of tauopathies [32]. Antitumor drugs targeting tau cysteine 322 and PHF6 hexapeptide prevent tau seeding and propagation of tau pathology [95]. A new drug discovery strategy making use of computational based virtual oligomerization inhibition has shown that epigallocatechin gallate (EGCG) inhibits PHF6 peptide aggregation and this was validated in tau seeding assay [96]. From this study, it is also reported that a good binding affinity of the inhibitors to tau aggregates may be insufficient to perform the full function of inhibiting tau oligomerization [96].

There are several other studies focusing on understanding heparin-induced β-sheet tau oligomers. In the study, β-sheet tau oligomers were characterized by size exclusion chromatography followed by staining with A11 tau oligomer specific antibody. These tau oligomers have been reported to decrease SH-SY5Y cell viability potentially through disruption of membrane integrity [31]. In another study, β-sheet tau oligomers were prepared for aggregation and dissociation studies with phosphorylation-based antibodies [97,98]. It has also been shown that baicalein suppresses tau aggregation by sequestering tau oligomers [99,100] or by initiating the formation of non-toxic tau oligomers [49]. Furthermore, fumarprotocetraric acid [101] and rutin [102] have been shown to attenuate tau pathology in cells and in mouse models of AD. Heparin-induced β-sheet tau oligomers have also been treated to macrophages and microglia and the study shows that macrophages phagocytose these extracellular tau oligomers more efficiently than microglia which are only able to degrade internalized tau oligomers upon lipopolysaccharide (LPS) stimulation [103].

Comparing β-sheet content in heparin-induced tau oligomers and fibrils, it was reported that tau oligomers have a high hydrophobicity with a lesser extent of internal
compact β-sheet structures, while mature tau fibrils contain both high content of internal compact β-sheet structures and hydrophobicity as characterized by ThS [89]. A notable transition from random coil to an increasing tendency of β-sheet formation during oligomerization has been observed by circular dichroism spectroscopy [89]. To study tau internalization and spreading, the uptake of ThT negative heparin-induced tau oligomers by human induced pluripotent stem cells (iPSCs) derived neurons has resulted in the accumulation of pathogenic tau and neuronal death [104]. Besides heparin, several other inducers such as hexafluorisopropanol [105] and arachidonic acid [106] have been used to induce formation of neurotoxic tau oligomers. Moreover, an oligomeric specific monoclonal antibody (TOC-1) has been generated using arachidonic acid induced tau aggregates as immunogens. TOC-1 has been reported to detect tau dimers and oligomeric species with little reactivity to tau fibrils [106–109].

4. Amyloid-Beta (Aβ)-Induced Tau Oligomerization

The cross-seeding potential of different amyloid species on tau aggregation has been tested on using Aβ fibrils, oligomers, and monomers as seeds to promote tau oligomerization and aggregation. It is reported that Aβ preformed oligomers, but not fibrils or monomers, convert disordered tau monomers into toxic tau oligomers with high β-sheet content. These toxic tau oligomers with spherical morphology are mostly stable as trimers in spherical morphology and they induced significantly more toxicity and neuronal dysfunctions in SH-SY5Y cells and in mice as compared to their monomeric or fibrillar counterparts [33,110,111]. Interestingly, despite containing β-sheet structure, Aβ-induced tau oligomers do not bind ThT or dyes that stain for amyloid structures, but bind strongly to 4,4′-dianilino-1,1′-binaphthyl-5,5′-disulfonic acid, dipotassium salt (bis-ANS), suggesting the presence of hydrophobic surfaces with conformational characteristics different from conventional fibrils [67]. A novel tau oligomer specific antibody (T22) has also been developed and used vastly in many in vitro cell-based studies, in vivo mouse studies as well as on human samples, suggesting the presence of this type of tau oligomeric strain in physiological relevant conditions [112–121]. The established Aβ-induced tau oligomers have also been used to study tau uptake [122], as well as seeding and propagation [19,123], where Aβ oligomers promote tau fibril uptake as seeds to potentiate intracellular tau aggregation [124]. Sonicated fibrils have also been shown to contain T22 positive oligomers which propagate with toxicity in neuronal cells, although it is unclear how the oligomers could arise from the sonication [125]. Another tau oligomer-specific monoclonal antibody (TOMA) has been developed based on Aβ-induced toxic tau oligomers. The administration of TOMA to mice expression human tau has shown to be effective in reducing tau oligomers and rescuing memory deficits [121,126].

Studies have furthered the drug discovery effort by therapeutic targeting of Aβ-induced tau oligomers, including the identification of chemicals and small molecule inhibitors [127]. Heparin oligosaccharides have been found to bind to Aβ-induced tau oligomers with nanomolar binding affinity and reduced the uptake of toxic tau oligomers, as well as rescued cell death in neuronal cells [64]. In two other studies, a derivative of Azure series of compounds such as Azure C and newly synthesized curcumin derivatives have been reported to modulate tau oligomerization and protect neuronal cell lines and primary cortical neurons from cell death [61,128]. Mechanistically, both Azure C and curcumin derivatives prevent neurotoxicity by converting toxic tau oligomers into more aggregated forms adopting non-toxic conformations and not by disrupting tau oligomers directly [61,128]. These results provide mechanistic insights into tau oligomerization and may serve as a basis for the discovery of new therapeutic agents targeting toxic tau oligomers.

5. Tau Oligomers Formed by Repeat Domains and Cleaved Species

There is higher aggregation propensity of the repeat domains and cleaved species of tau as compared to the full-length tau protein [18,129]. Protein fragments of tauRD with the deletion of lysine 280 (tauRDΔK), which is associated with FTDP-17, have been
shown to form stable and toxic tau oligomers containing β-sheet conformations [62,130]. To target these tauRDΔK tau oligomers, EGCG is capable of inhibiting tau oligomerization and rescuing toxicity in neuronal model cells [62]. In order to examine the molecular content of tauRDΔK oligomers, a study has characterized them based on 8-anilino-1-naphthalenesulfonic acid (ANS) and ThS profiles. Three main conformational states have been described with monomers having low ANS/low ThS, oligomers having high ANS/low ThS, and fibrils having high ANS/high ThS [34]. It has also been proposed that tauRDΔK oligomers do not adopt pronounced β-sheet conformation and they cause synaptotoxicity selectively without impairing overall cell viability [34]. The transient nature of tau aggregation makes it difficult to maintain the stability of preformed oligomers. The efficient labeling of tauRD with Alexa Fluor-488-C5-maleimide or N-ethyl maleimide has been shown to stabilize the resulting oligomers [35].

In terms of therapeutic targeting, curcumin and epinephrine are reported to disrupt tau oligomeric protofibrils formed by tau K3-R4 through molecular dynamics simulation [131], while a dimeric transient intermediate inhibits tau K18 fibril elongation [132]. Besides forming tau oligomers, tauRD is well known to form highly aggregated tau fibrillar species as characterized by the tau K18 FRET biosensor [133] and are capable of seeding and propagation of tau pathology [134].

6. Summary and Future Perspectives

With a pressing need to target AD and tauopathies which are currently untreatable, global efforts have been made to elucidate underlying disease mechanisms to facilitate the development of disease-modifying therapies as well as identify clinical phenotypes and robust biomarkers for early diagnosis [141]. In this review, we described several models of tau oligomerization using recombinant purified proteins and in cells as well as discuss the drug discovery efforts using these approaches. There are multiple other factors such as the role of phosphorylation [142,143] and liquid-liquid phase separation in tau oligomerization [144–146] that have to be taken into account to work towards achieving the identification of the true toxic tau species. While targeting toxic tau oligomers has been demonstrated to be effective in several pre-clinical studies [68,69,147], a caveat in specific targeting lies in need to disrupt or eliminate toxic tau oligomers, but not the non-toxic forms [148], which may aid in sequestering the toxic species. Advanced visualization and computational techniques such as machine learning-based classification [149] could further be developed and utilized to segregate these distinct tau species for more specific targeting. Besides being therapeutic targets, it has been proposed that quantifying the amount and level of tau oligomers may represent useful AD biomarkers [150]. With emerging tau-based clinical imaging techniques such as positron emission tomography (PET) [151–153] and magnetic resonance imaging (MRI) [154,155], the future development of tau oligomer targeted imaging modalities [156–159] would improve the diagnosis of AD and related tauopathies.
Funding: This study was supported by a Lee Kong Chian School of Medicine Dean’s Postdoctoral Fellowship to Chih Hung Lo (Grant Award Number 021207-00001) from Nanyang Technological University (NTU) Singapore.

Institutional Review Board Statement: Not applicable.

Informed Consent Statement: Not applicable.

Data Availability Statement: Not applicable.

Acknowledgments: The author would like to thank Jialiu Zeng for proofreading the manuscript.

Conflicts of Interest: The author declares no conflict of interest.

References

1. World Health Organization (WHO). The Top 10 Causes of Death. 2020. Available online: https://www.who.int/news-room/factsheets (accessed on 15 September 2022).

2. Wood, J.G.; Mirra, S.S.; Pollock, N.J.; Binder, L.I. Neurofibrillary tangles of Alzheimer disease share antigenic determinants with the axonal microtubule-associated protein tau (tau). Proc. Natl. Acad. Sci. USA 1986, 83, 4040–4043. [CrossRef] [PubMed]

3. Avila, J.; Lucas, J.J.; Pérez, M.; Hernández, F. Role of Tau Protein in Both Physiological and Pathological Conditions. Physiol. Rev. 2004, 84, 361–384. [CrossRef] [PubMed]

4. Bramblett, G.T.; Goedert, M.; Jakes, R.; Merrick, S.E.; Trojanowski, J.Q.; Lee, V.M.Y. Abnormal tau phosphorylation at Ser396 in Alzheimer’s disease recapitulates development and contributes to reduced microtubule binding. Neuron 1993, 10, 1089–1099. [CrossRef] [PubMed]

5. Sahara, N.; Maeda, S.; Takashima, A. Tau Oligomerization: A Role for Tau Aggregation Intermediates Linked to Neurodegeneration. Curr. Alzheimer Res. 2008, 5, 591–598. [CrossRef] [PubMed]

6. Ballatore, C.; Lee, V.M.Y.; Trojanowski, J.Q. Tau-mediated neurodegeneration in Alzheimer’s disease and related disorders. Nat. Rev. Neurosci. 2007, 8, 663. [CrossRef] [PubMed]

7. Gerson, J.E.; Castillo-Carranza, D.L.; Kayed, R. Advances in Therapeutics for Neurodegenerative Tauopathies: Moving toward the Specific Targeting of the Most Toxic Tau Species. ACS Chem. Neurosci. 2014, 5, 752–769. [CrossRef] [PubMed]

8. Maeda, S.; Sahara, N.; Saito, Y.; Murayama, S.; Ikai, A.; Takashima, A. Increased levels of granular tau oligomers: An early sign of brain aging and Alzheimer’s disease. Neurosci. Res. 2006, 54, 197–201. [CrossRef] [PubMed]

9. Cárdenas-Aguayo, M.D.C.; Gómez-Virgilio, L.; Derosa, S.; Meraz-Rios, M.A. The Role of Tau Oligomers in the Onset of Alzheimer’s Disease Neuropathology. ACS Chem. Neurosci. 2014, 5, 1178–1191. [CrossRef] [PubMed]

10. Liang, S.-Y.; Wang, Z.-T.; Tan, L.; Yu, J.-T. Tau Toxicity in Neurodegeneration. Mol. Neurobiol. 2022, 59, 3617–3634. [CrossRef]

11. Gerson, J.; Castillo-Carranza, D.L.; Sengupta, U.; Bodani, R.; Prough, D.S.; Dewitt, D.S.; Hawkins, B.E.; Kayed, R. Tau Oligomers Derived from Traumatic Brain injury Cause Cognitive Impairment and Accelerate Onset of Pathology in Htau Mice. J. Neurotrauma 2016, 33, 2034–2043. [CrossRef]

12. Hill, E.; Karikari, T.K.; Moflati, K.G.; Richardson, M.J.E.; Wall, M.J. Introduction of Tau Oligomers into Cortical Neurons Alters Action Potential Dynamics and Disrupts Synaptic Transmission and Plasticity. eNeuro 2019, 6, ENEURO.0166-19. [CrossRef] [PubMed]

13. Castillo-Carranza, D.L.; Nilson, A.N.; Van Skike, C.E.; Jahrling, J.B.; Patel, K.; Garach, P.; Gerson, J.E.; Sengupta, U.; Abisambra, J.; Nelson, P.; et al. Cerebral Microvascular Accumulation of Tau Oligomers in Alzheimer’s Disease and Related Tauopathies. Aging Dis. 2017, 8, 257–266. [CrossRef] [PubMed]

14. Wittmann, C.W.; Wszeolk, M.F.; Shulman, J.M.; Salvaterra, P.M.; Lewis, J.; Hutton, M.; Feany, M.B. Tauopathy in Drosophila: Neurodegeneration without Neurofibrillary Tangles. Science 2001, 293, 711–714. [CrossRef] [PubMed]

15. Santacruz, K.; Lewis, J.; Spires, T.; Paulson, J.; Kotilinek, L.; Ingelsson, M.; Guimaraes, A.; Detry, M.; Ramsden, M.; McGowan, E.; et al. Tau suppression in a neurodegenerative mouse model improves memory function. Science 2005, 309, 476–481. [CrossRef] [PubMed]

16. Berger, Z.; Roder, H.; Hanna, A.; Carlsson, A.; Rangachari, V.; Yue, M.; Wszeolk, Z.; Ashe, K.; Knight, J.; Dickson, D.; et al. Accumulation of Pathological Tau Species and Memory Loss in a Conditional Model of Tauopathy. J. Neurosci. 2007, 27, 3650–3662. [CrossRef] [PubMed]

17. Cowan, C.; Mudher, A. Are Tau Aggregates Toxic or Protective in Tauopathies? Front. Neurol. 2013, 4, 114. [CrossRef] [PubMed]

18. Limorenko, G.; Lashuel, H.A. Revisiting the grammar of Tau aggregation and pathology formation: How new insights from brain pathology are shaping how we study and target Tauopathies. Chem. Soc. Rev. 2022, 51, 515–565. [CrossRef] [PubMed]

19. Gerson, J.E.; Kayed, R. Formation and propagation of tau oligomeric seeds. Front. Neurol. 2013, 4, 93. [CrossRef] [PubMed]

20. Zhao, J.; Wu, H.; Tang, X.-Q. Tau internalization: A complex step in tau propagation. Ageing Res. Rev. 2021, 67, 101272. [CrossRef] [PubMed]

21. Congdon, E.E.; Jiang, Y.; Sigurdsson, E.M. Targeting tau only extracellularly is likely to be less efficacious than targeting it both intra- and extracellularly. Semin. Cell Dev. Biol. 2022, 126, 125–137. [CrossRef] [PubMed]

22. Guzmán-Martínez, L.; Farias, G.A.; Maccioni, R.B. Tau oligomers as potential targets for Alzheimer’s diagnosis and novel drugs. Front. Neurol. 2013, 4, 167. [CrossRef] [PubMed]
23. Kopecina, K.J.; Hyman, B.T.; Spires-Jones, T.L. Soluble forms of tau are toxic in Alzheimer’s disease. *Transl. Neurosci.* 2012, 3, 223–233. [CrossRef] [PubMed]

24. Ward, S.M.; Himmelstein, D.S.; Lancia, J.K.; Binder, L.I. Tau oligomers and tau toxicity in neurodegenerative disease. *Biochem. Soc. Trans.* 2012, 40, 667–671. [CrossRef] [PubMed]

25. Niewiadomska, G.; Niewiadomski, W.; Steczkowska, M.; Gasiorowska, A. Tau Oligomers Neurotoxicity. *Life* 2021, 11, 28. [CrossRef]

26. Orr, M.E.; Sullivan, A.C.; Frost, B. A Brief Overview of Tauopathy: Causes, Consequences, and Therapeutic Strategies. *Trends Pharmacol. Sci.* 2017, 38, 637–648. [CrossRef]

27. Cummings, J.; Lee, G.; Nahed, P.; Kambar, M.E.Z.N.; Zhong, K.; Forseca, J.; Taghva, K. Alzheimer’s disease drug development pipeline: 2022. *Alzheimer’s Dement. Transl. Res. Clin. Interv.* 2022, 8, e12295. [CrossRef]

28. Soeda, Y.; Saito, M.; Maeda, S.; Ishida, K.; Nakamura, A.; Kojima, S.; Takashima, A. Methylene Blue Inhibits Formation of Tau Fibrils but not of Granular Tau Oligomers: A Plausible Key to Understanding Failure of a Clinical Trial for Alzheimer’s Disease. *J. Alzheimer’s Dis.* 2019, 68, 1677–1686. [CrossRef]

29. Spires-Jones, T.L.; Friedman, T.; Pitsick, R.; Polydoro, M.; Roe, A.; Carlson, G.A.; Hyman, B.T. Methylene blue does not reverse existing neurofibrillary tangle pathology in the r1g4510 mouse model of tauopathy. *Neurosci. Lett.* 2014, 562, 63–68. [CrossRef]

30. Maeda, S.; Sahara, N.; Saito, Y.; Murayama, M.; Yoshiike, Y.; Kim, H.; Miyasaka, T.; Murayama, S.; Ikai, A.; Takashima, A. Granular Tau Oligomers as Intermediates of Tau Filaments. *Biochemistry* 2007, 46, 3856–3861. [CrossRef]

31. Flach, K.; Hilbrich, I.; Schiffrin, A.; Gärtnert, U.; Krüger, M.; Leonhardt, M.; Waschpyk, H.; Wick, L.; Arendt, T.; Holzer, M. Tau Oligomers Impair Artificial Membrane Integrity and Cellular Viability. *J. Biol. Chem.* 2012, 287, 43223–43233. [CrossRef]

32. Soeda, Y.; Yoshihikawa, M.; Almeida, O.F.X.; Sumioka, I.; Maeda, S.; Osada, H.; Kondoh, Y.; Saito, A.; Miyasaka, T.; Kimura, T.; et al. Toxic tau oligomer formation blocked by capping of cysteine residues with 1,2-dihydroxybenzene groups. *Nat. Commun.* 2015, 6, 10216. [CrossRef] [PubMed]

33. Lasagna-Reeves, C.A.; Castillo-Carranza, D.L.; Guerrero-Muñoiz, M.J.; Jackson, G.R.; Kayed, R. Preparation and Characterization of Neurotoxic Tau Oligomers. *Biochemistry* 2010, 49, 10039–10041. [CrossRef] [PubMed]

34. Kaniyappan, S.; Chandupatla, R.R.; Mandelkow, E.-M.; Mandelkow, E. Extracellular low-n oligomers of tau cause selective synaptotoxicity without affecting cell viability. *Alzheimer’s Dement.* 2017, 13, 1270–1291. [CrossRef] [PubMed]

35. Karikari, T.K.; Nagel, D.A.; Grainger, A.; Clarke-Bland, C.; Hill, E.J.; Molfat, K.G. Preparation of stable tau oligomers for cellular and biochemical studies. *Anal. Biochem.* 2019, 566, 67–74. [CrossRef] [PubMed]

36. Tian, H.; Davidowitz, E.; Lopez, P.; Emadi, S.; Moore, J.; Siers, K. Trimeric Tau Is Toxic to Human Neuronal Cells at Low Nanomolar Concentrations. *Int. J. Cell Biol.* 2013, 2013, 260787. [CrossRef] [PubMed]

37. Mirbaha, H.; Chen, D.; Mullapudi, V.; Terpack, S.J.; White, C.L., 3rd; Joachimiak, L.A.; Diamond, M.I. Seed-competent tau monomer initiates pathology in a tauopathy mouse model. *J. Biol. Chem.* 2022, 298, 102163. [CrossRef] [PubMed]

38. Saroja, S.R.; Sharma, A.; Hof, P.R.; Pereira, A.C. Differential expression of tau species and the association with cognitive decline and synaptic loss in Alzheimer’s disease. *Alzheimer’s Dement.* 2022, 18, 1602–1615. [CrossRef]

39. Kovacs, G.G. Invited review: Neuropathology of tauopathies: Principles and practice. *Neuropathol. Appl. Neurobiol.* 2015, 41, 3–23. [CrossRef]

40. Ghetti, B.; Oblak, A.L.; Boeve, B.F.; Johnson, K.A.; Dickerson, B.C.; Goedert, M. Invited review: Frontotemporal dementia caused by microtubule-associated protein tau gene (MAPT) mutations: A chameleon for neuropathology and neuroimaging. *Neuropathol. Appl. Neurobiol.* 2015, 41, 24–46. [CrossRef]

41. Hromadkova, L.; Siddiqi, M.K.; Liu, H.; Safar, J.G. Populations of Tau Conformers Drive Prion-like Strain Effects in Alzheimer’s Disease and Related Dementias. *Cells* 2022, 11, 2997.

42. Vaquer-Alicea, J.; Diamond, M.I.; Joachimiak, L.A. Tau strains shape disease. *Acta Neuropathol.* 2021, 142, 57–71. [CrossRef] [PubMed]

43. Nath, A.; Sannalkorpi, M.; Dewitt, D.C.; Trexler, A.J.; Elbaum-Garfinkle, S.; O’hern, C.S.; Rhoades, E. The conformational ensembles of α-synuclein and tau: Combining single-molecule FRET and simulations. *Biophys. J.* 2012, 103, 1940–1949. [CrossRef] [PubMed]

44. Gerson, J.E.; Mudher, A.; Kayed, R. Potential mechanisms and implications for the formation of tau oligomeric strains. *Crit. Rev. Biochem. Mol. Biol.* 2016, 51, 492–498. [CrossRef] [PubMed]

45. Sharma, A.M.; Thomas, T.L.; Woodard, D.R.; Ksander, O.M.; Diamond, M.I. Tau monomer encodes strains. *eLife* 2018, 7, e37813. [CrossRef]

46. Mirbaha, H.; Chen, D.; Morazova, O.A.; Ruff, K.M.; Sharma, A.M.; Liu, X.; Goodarzi, M.; Pappu, R.V.; Colby, D.W.; Mirzaei, H.; et al. Inert and seed-competent tau monomers suggest structural origins of aggregation. *eLife* 2018, 7, e36584. [CrossRef]

47. Huang, R.Y.C.; Jacob, R.E.; Sankaranarayanan, S.; Yang, L.; Ahlijianian, M.; Tao, L.; Tymia, A.A.; Chen, G. Probing Conformational Dynamics of Tau Protein by Hydrogen/Deuterium Exchange Mass Spectrometry. *J. Am. Soc. Mass Spectrom.* 2018, 29, 174–182. [CrossRef]

48. Shahie, S.S.; Guerrero-Muñoiz, M.J.; Castillo-Carranza, D.L. Tau Oligomers: Cytotoxicity, Propagation, and Mitochondrial Damage. *Front. Aging Neurosci.* 2017, 9, 83. [CrossRef]

49. Sonawane, S.K.; Uversky, V.N.; Chinnathambi, S. Baicalein inhibits heparin-induced Tau aggregation by initializing non-toxic Tau oligomer formation. *Cell Commun. Signal.* 2021, 19, 16. [CrossRef]
50. Mamun, A.A.; Uddin, M.S.; Mathew, B.; Ashraf, G.M. Toxic tau: Structural origins of tau aggregation in Alzheimer’s disease. *Neural Regen. Res.* 2020, 15, 1417–1420.

51. Penke, B.; Srécs, M.; Bogár, F. Oligomerization and Conformational Change Turn Monomeric β-Amyloid and Tau Proteins Toxic. Their Role in Alzheimer’s Pathogenesis. *Molecules* 2020, 25, 1659. [CrossRef]  

52. Lo, C.H.; Lim, C.K.-W.; Ding, Z.; Wickramasinghe, S.P.; Braun, A.R.; Ashe, K.H.; Roohad, E.; Thomas, D.D.; Sachs, J.N. Targeting the ensemble of heterogeneous tau oligomers in cells: A novel small molecule screening platform for tauopathies. *Alzheimer’s Dement.* 2019, 15, 1489–1502. [CrossRef] [PubMed]

53. Nizynski, B.; Nieznanska, H.; Dec, R.; Boyko, S.; Dzwolak, W.; Nieznanski, K. Amyloidogenic cross-seeding of Tau protein: Transient emergence of structural variants of fibrils. *PLoS ONE* 2018, 13, e0201182. [CrossRef] [PubMed]

54. Karikari, T.K.; Turner, A.; Stass, R.; Lee, L.C.Y.; Wilson, B.; Nagel, D.A.; Hill, E.J.; Moffat, K.G. Expression and purification of tau protein and its frontotemporal dementia variants using a cleavable histidine tag. *Protein Expr. Purif.* 2017, 130, 44–54. [CrossRef] [PubMed]

55. Götz, J.; Xia, D.; Leinenga, G.; Chew, Y.L.; Nicholas, H. What Renders TAU Toxic. *Front. Neurol.* 2013, 4, 72. [CrossRef] [PubMed]

56. Gendron, T.F.; Petrucelli, L. The role of tau in neurodegeneration. *Mol. Neurodegener.* 2009, 4, 13. [CrossRef] [PubMed]

57. Blair, L.J.; Nordhues, B.A.; Hill, S.E.; Scaglione, K.M.; O’leary, J.C., 3rd; Fontaine, S.N.; Breydo, L.; Zhang, B.; Li, P.; Wang, L.; et al. Accelerated neurodegeneration through chaperone-mediated oligomerization of tau. *J. Clin. Investig.* 2013, 123, 4158–4169. [CrossRef] [PubMed]

58. Novak, P.; Cehlar, O.; Skrabana, R.; Novak, M. Tau Conformation as a Target for Disease-Modifying Therapy: The Role of Truncation. *J. Alzheimer’s Dis.* 2018, 64, S535–S546. [CrossRef]

59. Avila, J.; Pallas, N.; Bobón, M.; Sayas, C.L.; Hernandez, F. Intracellular and extracellular microtubule associated protein tau as a therapeutic target in Alzheimer disease and other tauopathies. *Expert Opin. Ther. Targets* 2016, 20, 653–661. [CrossRef]

60. Lauretti, E.; Pratìcò, D. Alzheimer’s disease: Phenotypic approaches using disease models and the targeting of tau protein. *Expert Opin. Ther. Targets* 2020, 24, 319–330. [CrossRef]

61. Lo Cascio, F.; Kayed, R. Azure C Targets and Modules Toxic Tau Oligomers. *ACS Chem. Neurosci.* 2018, 9, 1317–1326. [CrossRef]

62. Webst, H.J.; Sharma, A.; Diamond, M.I.; Wanker, E.E.; Bieschke, J. The green tea polyphenol (-)-epigallocatechin gallate prevents the aggregation of tau protein into toxic oligomers at substoichiometric ratios. *FEBS Lett.* 2015, 589, 77–83. [CrossRef] [PubMed]

63. Rane, J.S.; Bhaumik, P.; Panda, D. Curcumin Inhibits Tau Aggregation and Disintegrates Preformed Tau Filaments in vitro. *J. Alzheimer’s Dis.* 2017, 60, 999–1014. [CrossRef] [PubMed]

64. Wang, P.; Lo Cascio, F.; Gao, J.; Kayed, R.; Huang, X. Binding and neurotoxicity mitigation of toxic tau oligomers by synthetic heparin like oligosaccharides. *Chem. Commun.* 2018, 54, 10120–10123. [CrossRef] [PubMed]

65. Baggett, D.W.; Nath, A. The Rational Discovery of a Tau Aggregation Inhibitor. *Biochemistry* 2018, 57, 6099–6107. [CrossRef] [PubMed]

66. Wang, D.; Huang, X.; Yan, L.; Zhou, L.; Yan, C.; Wu, J.; Su, Z.; Huang, Y. The Structure Biology of Tau and Clue for Aggregation Protein and its frontotemporal dementia variants using a cleavable histidine tag. *Protein Expr. Purif.* 2017, 130, 44–54. [CrossRef] [PubMed]

67. Giovannini, J.; Smeralda, W.; Jouanne, M.; Sopkova-De Oliveira Santos, J.; Catto, M.; Voisin-Chiret, A.S. Tau protein aggregation: Key features to improve drug discovery screening. *Drug Discov. Today* 2020, 25, 130–138. [CrossRef] [PubMed]

68. Wang, P.; Lo Cascio, F.; Gao, J.; Kayed, R.; Huang, X. Binding and neurotoxicity mitigation of toxic tau oligomers by synthetic heparin like oligosaccharides. *Chem. Commun.* 2018, 54, 10120–10123. [CrossRef] [PubMed]

69. Wang, D.; Huang, X.; Yan, L.; Zhou, L.; Yan, C.; Wu, J.; Su, Z.; Huang, Y. The Structure Biology of Tau and Clue for Aggregation Inhibitor Design. *Protein J.* 2021, 40, 656–668. [CrossRef]

70. Giovannini, J.; Smeralda, W.; Jouanne, M.; Sopkova-De Oliveira Santos, J.; Catto, M.; Voisin-Chiret, A.S. Tau protein aggregation: Key features to improve drug discovery screening. *Drug Discov. Today* 2020, 25, 1284–1297. [CrossRef] [PubMed]

71. Umeda, T.; Sakai, A.; Shigemori, K.; Yokota, A.; Kumagai, T.; Tomiyama, T. Oligomer-Targeting Prevention of Neurodegenerative Dementia by Intranasal Rifampicin and Resveratrol Combination—A Preclinical Study in Model Mice. *Front. Neurosci.* 2021, 15, 763476. [CrossRef]

72. Umeda, T.; Uekubo, R.; Shigemori, K.; Eguchi, H.; Tomiyama, T. Nasal Rifampicin Halts the Progression of Tauopathy by Inhibiting Tau Oligomer Propagation in Alzheimer Brain Extract-Injected Mice. *Biomedicines* 2022, 10, 297. [CrossRef]

73. Medina, M. An Overview on the Clinical Development of Tau-Based Therapeutics. *Int. J. Mol. Sci.* 2018, 19, 1160. [CrossRef]

74. Giacobini, E.; Voisin-Chiret, A.S. What Renders TAU Toxic. *Front. Neurosci.* 2015, 9, 677. [CrossRef] [PubMed]

75. Lee, H.E.; Lim, D.; Lee, J.Y.; Lim, S.M.; Pae, A.N. Recent tau-targeted clinical strategies for the treatment of Alzheimer’s disease. *Future Med. Chem.* 2019, 11, 1845–1848. [CrossRef]

76. Lo, C.H.; Sachs, J.N. The role of wild-type tau in Alzheimer’s disease and related tauopathies. *J. Life Sci.* 2020, 2, 1–17. [CrossRef] [PubMed]

77. Hao, C.; Tzu-Kang, S.; Hui-Yun, C. Tauopathy. In *Cognitive Disorders*; Foyaca, S.H., Ed.; IntechOpen: Rijeka, Croatia, 2018; Chapter 3.

78. Maeda, S.; Takashima, A. Tau Oligomers. In *Tau Biology*; Takashima, A., Wolozin, B., Bue, L., Eds.; Springer: Singapore, 2019; pp. 373–380.

79. Manassero, G.; Guggiari, M.; Monteleone, D.; Vasciaveo, V.; Butenko, O.; Tamagno, E.; Arancio, O.; Tabaton, M. Dual Mechanism of Toxicity for Extracellular Injection of Tau Oligomers versus Monomers in Human Tau Mice. *J. Alzheimer’s Dis.* 2017, 59, 743–751. [CrossRef]

80. Shahpasand-Kroner, H.; Portillo, J.; Lantz, C.; Seidler, P.M.; Sarafian, N.; Loo, J.A.; Bitan, G. Three-repeat and four-repeat tau isoforms form different oligomers. *Protein Sci.* 2022, 31, 613–627. [CrossRef] [PubMed]

81. Lo, C.H. Recent advances in cellular biosensor technology to investigate tau oligomerization. *Bioeng. Transl. Med.* 2021, 6, e10231. [CrossRef] [PubMed]

82. Li, X.C.; Hu, Y.; Wang, Z.H.; Luo, Y.; Zhang, Y.; Liu, X.P.; Feng, Q.; Wang, Q.; Ye, K.; Liu, G.P.; et al. Human wild-type full-length tau accumulation disrupts mitochondrial dynamics and the functions via increasing mitofusins. *Sci. Rep.* 2016, 6, 24756. [CrossRef]

83. Ozcelik, S.; Sprenger, F.; Skachkova, Z.; Fraser, G.; Abramowski, D.; Clavaguera, F.; Probst, A.; Frank, S.; Müller, M.; Staufenbiel, M.; et al. Co-expression of truncated and full-length tau induces severe neurotoxicity. *Mol. Psychiatry* 2016, 21, 1790–1798. [CrossRef]
81. Pickhardt, M.; Biernat, J.; Hübßchmann, S.; Dennissen, F.J.A.; Timm, T.; Aho, A.; Mandelkow, E.M.; Mandelkow, E. Time course of Tau toxicity and pharmacologic prevention in a cell model of Tauopathy. Neurobiol. Aging 2017, 57, 47–63. [CrossRef]

82. Hu, J.Y.; Zhang, D.L.; Liu, X.L.; Li, X.S.; Cheng, X.Q.; Chen, J.; Du, H.N.; Liang, Y. Pathological concentration of zinc dramatically accelerates abnormal aggregation of full-length human Tau and thereby significantly increases Tau toxicity in neuronal cells. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 414–427. [CrossRef]

83. Tepper, K.; Biernat, J.; Kumar, S.; Wegmann, S.; Timm, T.; Hübßchmann, S.; Redecke, L.; Mandelkow, E.M.; Müller, D.J.; Mandelkow, E. Oligomer formation of tau protein hyperphosphorylated in cells. J. Biol. Chem. 2014, 289, 34389–34407. [CrossRef]

84. Shin, S.; Kim, D.; Song, J.Y.; Jeong, H.; Hyeon, S.J.; Kowall, N.W.; Ryu, H.; Pae, A.N.; Lim, S.; Kim, Y.K. Visualization of soluble tau oligomers in TauP301L-BiFC transgenic mice demonstrates the progression of tauopathy. Prog. Neurobiol. 2020, 187, 101782. [CrossRef] [PubMed]

85. Braun, A.R.; Liao, E.E.; Horvath, M.; Kalra, P.; Young, M.C.; Kochen, N.N.; Brown, R.; Evans, M.D.; et al. Potent inhibitors of toxic alpha-synuclein identified via cellular time-resolved FRET biosensors. NPJ Park. Dis. 2021, 7, 52. [CrossRef] [PubMed]

86. Lo, C.H.; Pandey, N.K.; Lim, C.K.-W.; Ding, Z.; Tao, M.; Thomas, D.D.; Langen, R.; Sachs, J.N. Discovery of Small Molecule Inhibitors of Huntingtin Exon 1 Aggregation by FRET-Based High-Throughput Screening in Living Cells. ACS Chem. Neurosci. 2020, 11, 2286–2295. [CrossRef] [PubMed]

87. Dong, X.; Qi, R.; Qiao, Q.; Li, X.; Li, F.; Wan, J.; Zhang, Q.; Wei, G. Heparin remodels the microtubule-binding repeat R3 of Tau towards fibril-prone conformations. Phys. Chem. Chem. Phys. 2023, 23, 20406–20418. [CrossRef] [PubMed]

88. Fichou, Y.; Vigers, M.; Goring, A.K.; Eschmann, N.A.; Han, S. Heparin-induced tau filaments are structurally heterogeneous and differ from Alzheimer’s disease filaments. Chem. Commun. 2018, 54, 4573–4576. [CrossRef] [PubMed]

89. Das, R.; Balmik, A.A.; Chinnathambi, S. Phagocytosis of full-length Tau oligomers by Actin-remodeling of activated microglia. J. Neuroinflamm. 2020, 17, 10. [CrossRef]

90. Sahara, N.; Maeda, S.; Murayama, M.; Suzuki, T.; Dohmae, N.; Yen, S.-H.; Takashima, A. Assembly of two distinct dimers and higher-order oligomers from full-length tau. Eur. J. Neurosci. 2007, 25, 3020–3029. [CrossRef]

91. Chidambaram, H.; Chinnathambi, S. Role of cysteines in accelerating Tau filament formation. J. Biol. Mol. Struct. Dyn. 2022, 40, 4366–4375. [CrossRef]

92. Saito, T.; Chiku, T.; Oka, M.; Wada-Kakuda, S.; Nobuhara, M.; Oba, T.; Shinno, K.; Abe, S.; Asada, A.; Sumioka, A.; et al. Disulfide bond formation in microtubule-associated tau protein promotes tau accumulation and toxicity in vivo. Hum. Mol. Genet. 2021, 30, 1955–1967. [CrossRef]

93. Hellén, M.; Bhattacharjee, A.; Uronen, R.-L.; Huttunen, H.J. Membrane interaction and disulphide-bridge formation in the unconventional secretion of Tau. Biosci. Rep. 2021, 41, BSRR20210148. [CrossRef] [PubMed]

94. Haque, M.M.; Kim, D.; Kim, D.J.; Chang, Y.-T.; Ha, H.-H.; Kim, Y.K. Inhibition of tau aggregation by a rosamine derivative that blocks tau intermolecular disulfide cross-linking. Amyloid 2014, 21, 185–190. [CrossRef] [PubMed]

95. Annadurai, N.; Malina, L.; Salmona, M.; Diomede, L.; Bastone, A.; Cagnotto, A.; Romeo, M.; Šreiber, M.; Berka, K.; Otyepka, M.; et al. Antitumour drugs targeting tau R3 VQIVYK and Cys322 prevent seeding of endogenous tau aggregates by exogenous seeds. FEBS J. 2022, 289, 1929–1949. [CrossRef] [PubMed]

96. Man, V.H.; Lin, D.; He, X.; Gao, J.; Wang, J. Joint Computational/Cell-Based Approach for Screening Inhibitors of Tau Oligomerization: A Proof-of-Concept Study. J. Alzheimer’s Dis. 2022, 89, 107–119. [CrossRef] [PubMed]

97. Subramanian, S.; Savanur, G.; Madhavadas, S. Passive immunization targeting the N-terminal region of phosphorylated tau reduces the spatial memory deficits in non-transgenic tauopathy model rats. Biochem. Biophys. Res. Commun. 2017, 483, 585–589. [CrossRef] [PubMed]

98. Subramanian, S.; Savanur, G. Antibodies directed to the phospho-tau peptide (residues 68–71) improves spatial memory in okadaic acid induced tauopathy model rats. Biochim. Biophys. Acta Mol. Basis Dis. 2017, 1863, 414–427. [CrossRef]

99. Sun, X.-Y.; Li, L.-J.; Dong, Q.-X.; Zhu, J.; Huang, Y.-R.; Hou, S.-J.; Yu, X.-L.; Liu, R.-T. Rutin prevents tau pathology and neuroinflammation in a mouse model of Alzheimer’s disease. J. Neuroinflamm. 2021, 18, 131. [CrossRef]

100. Majerova, P.; Zilkova, M.; Kazmerova, Z.; Kovac, A.; Paholikova, K.; Kovacech, B.; Zilka, N.; Novak, M. Microglia display modest phagocytic capacity for extracellular tau oligomers. J. Neuroinflamm. 2014, 11, 161. [CrossRef]

101. Usenovic, M.; Niroomand, S.; Drolet, R.E.; Yao, L.; Gaspar, R.C.; Hatcher, N.G.; Schachter, J.; Renger, J.J.; Parmentier-Batteur, S. Internalized Tau Oligomers Cause Neurodegeneration by Inducing Accumulation of Pathogenic Tau in Human Neurons Derived from Induced Pluripotent Stem Cells. J. Neurosci. 2015, 35, 14234–14250. [CrossRef]

102. Gómez-Ramos, A.; Díaz-Hernández, M.; Cuadros, R.; Hernández, F.; Avila, J. Extracellular tau is toxic to neuronal cells. FEBS Lett. 2006, 580, 4842–4850. [CrossRef] [PubMed]
106. Patterson, K.R.; Remmers, C.; Fu, Y.; Brooker, S.; Kanaan, N.M.; Vana, L.; Ward, S.; Reyes, J.F.; Philibert, K.; Glucksman, M.J.; et al. Characterization of prefibrillar Tau oligomers in vitro and in Alzheimer disease. *J. Biol. Chem.* **2011**, *286*, 23063-23076. [CrossRef] [PubMed]

107. Ward, S.M.; Himmelstein, D.S.; Lancia, J.K.; Fu, Y.; Patterson, K.R.; Binder, L.I. TOC1: Characterization of a Selective Oligomeric Tau Antibody. *J. Alzheimer’s Dis.* **2013**, *37*, 593-602. [CrossRef] [PubMed]

108. Patterson, K.R.; Ward, S.; Binder, L. Prefibrillar Tau Oligomers in Mild Cognitive Impairment and Alzheimer’s Disease. *Neurodegener. Dis.* **2014**, *13*, 151-153. [CrossRef] [PubMed]

109. Zheng, J.; Akbarn, M.; Schirmer, C.; Reynaert, M.-L.; Loyens, A.; Lefebvre, B.; Buée, L.; Croette, D.U.; Galas, M.-C.; Bohr, V.A. Hippocampal tau oligomerization early in tau pathology coincides with a transient alteration of mitochondrial homeostasis and DNA repair in a mouse model of tauopathy. *Acta Neuropathol. Commun.* **2020**, *8*, 25. [CrossRef]

110. Pracut, M.; Sengupta, U.; Kayed, R. Tau Oligomers as Pathogenic Seeds: Preparation and Propagation In Vitro and In Vivo. *Methods Mol. Biol.* **2017**, *1523*, 141-157.

111. Lasagna-Reeves, C.A.; Castillo-Carranza, D.L.; Sengupta, U.; Clos, A.L.; Jackson, G.R.; Kayed, R. Tau oligomers impair memory and induce synaptic and mitochondrial dysfunction in wild-type mice. *Mol. Neurodegener.* **2011**, *6*, 39. [CrossRef]

112. Lasagna-Reeves, C.A.; Castillo-Carranza, D.L.; Sengupta, U.; Guerrero-Munoz, M.J.; Kiritsi, T.; Neugebauer, V.; Jackson, G.R.; Kayed, R. Alzheimer brain-derived tau oligomers propagate pathology from endogenous tau. *Sci. Rep.* **2012**, *2*, 700. [CrossRef]

113. Castillo-Carranza, D.L.; Gerson, J.E.; Sengupta, U.; Guerrero-Muñoz, M.J.; Lasagna-Reeves, C.A.; Kayed, R. Specific Targeting of Tau Oligomers in Hhau Mouse Prevents Cognitive Impairment and Tau Pathology Following Injection with Brain-Derived Tau Oligomeric Seeds. *J. Alzheimer’s Dis.* **2014**, *40*, S97-S111. [CrossRef]

114. Violete, M.; Chauderlier, A.; Delattre, L.; Tardivel, M.; Chouala, M.S.; Sultan, A.; Marciniak, E.; Humez, S.; Binder, L.; Kayed, R.; et al. Prefibrillar Tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo. *Neurobiol. Dis.* **2015**, *52*, 540-551. [CrossRef]

115. Umeda, T.; Ono, K.; Sakai, A.; Yamashita, M.; Mizuguchi, M.; Klein, W.L.; Yamada, M.; Mori, H.; Tomiyama, T. Rifampicin is a candidate preventive medicine against amyloid-β and tau oligomers. *Brain* **2016**, *139*, 1568-1586. [CrossRef] [PubMed]

116. Fä, M.; Puzzo, D.; Piacentini, R.; Staniszevski, A.; Zhang, H.; Baltrons, M.A.; Li Puma, D.D.; Chatterjee, I.; Li, J.; Saeed, F.; et al. Extracellular Tau Oligomers Produce An Immediate Impairment of LTP and Memory. *Sci. Rep.* **2016**, *6*, 19393. [CrossRef] [PubMed]

117. Nilson, A.N.; English, K.C.; Gerson, J.E.; Barton Whittle, T.; Nicolas Crain, C.; Xue, J.; Sengupta, U.; Castillo-Carranza, D.L.; Wang, W.; Gupt, P.; et al. Tau Oligomers Associate with Inflammation in the Brain and Retina of Tauopathy Mice and in Neurodegenerative Diseases. *J. Alzheimer's Dis.* **2017**, *55*, 1083-1099. [CrossRef] [PubMed]

118. Kolarova, M.; Sengupta, U.; Bartos, A.; Ricny, J.; Kayed, R. Tau Oligomers in Sera of Patients with Alzheimer’s Disease and Aged Controls. *J. Alzheimer’s Dis.* **2017**, *58*, 471-478. [CrossRef] [PubMed]

119. Comerota, M.M.; Tumurbaatar, B.; Krishnan, B.; Kayed, R.; Taglialetela, G. Near Infrared Light Treatment Reduces Synaptic Levels of Toxic Tau Oligomers in Two Transgenic Mouse Models of Human Tauopathies. *Mol. Neurobiol.* **2019**, *56*, 3341-3355. [CrossRef] [PubMed]

120. Puangmalai, N.; Bhatt, N.; Montalbano, M.; Sengupta, U.; Gaikwad, S.; Ventura, F.; Mcallen, S.; Ellsworth, A.; Garcia, S.; Kayed, R. Internalization mechanisms of brain-derived tau oligomers from patients with Alzheimer’s disease, progressive supranuclear palsy and dementia with Lewy bodies. *Cell Death Dis.* **2020**, *11*, 314. [CrossRef]

121. Bitar, A.; Bhatt, N.; Hasan, T.F.; Montalbano, M.; Puangmalai, N.; Mccalen, S.; Ellsworth, A.; Carretero Murillo, M.; Taglialetela, G.; Lucke-Wold, B.; et al. Neurotoxic tau oligomers alter the nucleic acid protective function of Tau in hippocampal neurons in vivo. *Neurobiol. Dis.* **2019**, *108*, S97-S111. [CrossRef]

122. Clavaguera, F.; Grueninger, F.; Tolnay, M. Intercellular transfer of tau aggregates and spreading of tau pathology: Implications for therapeutic strategies. *Neuropharmacology* **2014**, *76*, 9-15. [CrossRef]

123. Guerrero-Muñoz, M.J.; Gerson, J.; Castillo-Carranza, D.L. Tau Oligomers: The Toxic Player at Synapses in Alzheimer’s Disease. *Front. Cell. Neurosci.* **2015**, *9*, 464. [CrossRef]

124. Shin, W.S.; Di, J.; Cao, Q.; Li, B.; Seidler, P.M.; Murray, K.A.; Bitan, G.; Jiang, L. Amyloid β-protein oligomers promote the uptake of tau fibril seeds potentiating intracellular tau aggregation. *Alzheimer’s Res. Ther.* **2019**, *11*, 86. [CrossRef]

125. Ghag, G.; Bhatt, N.; Cantu, D.V.; Guerrero-Munoz, M.J.; Ellsworth, A.; Sengupta, U.; Kayed, R. Soluble tau aggregates, not large fibrils, are the toxic species that display seeding and cross-seeding behavior. *Protein Sci.* **2018**, *27*, 1901-1909. [CrossRef] [PubMed]

126. Castillo-Carranza, D.L.; Sengupta, U.; Guerrero-Muño, M.J.; Lasagna-Reeves, C.A.; Gerson, J.E.; Singh, G.; Estes, D.M.; Barrett, A.D.T.; Dineley, K.T.; Jackson, G.R.; et al. Passive Immunization with Tau Oligomer Monoclonal Antibody Reverses Tauopathy Phenotypes without Affecting Hyperphosphorylated Neurofibrillary Tangles. *J. Neurosci.* **2014**, *34*, 4260-4272. [CrossRef] [PubMed]

127. Guerrero-Muñoz, M.J.; Castillo-Carranza, D.L.; Kayed, R. Therapeutic approaches against common structural features of toxic oligomers shared by multiple amyloidogenic proteins. *Biochem. Pharmacol.* **2014**, *88*, 468-478. [CrossRef] [PubMed]

128. Lo Cascio, F.; Puangmalai, N.; Ellsworth, A.; Bucchieri, F.; Pace, A.; Palumbo Piccionello, A.; Kayed, R. Toxic Tau Oligomers Modulated by Novel Curcumin Derivatives. *Sci. Rep.* **2019**, *9*, 19011. [CrossRef]

129. Lee, S.; Shea, T.B. Caspase-Mediated Truncation of Tau Potentiates Aggregation. *Int. J. Alzheimer’s Dis.* **2012**, *2012*, 731063. [CrossRef]

130. Ono, K.; Yamada, M. Low-n oligomers as therapeutic targets of Alzheimer’s disease. *J. Neurochem.* **2011**, *117*, 19-28. [CrossRef]

131. Zhou, Y.; Qi, B.; Tan, J.; Sun, Y.; Gong, Y.; Zhang, Q. Mechanistic insight into the disruption of Tau R3–R4 protofibrils by curcumin and epinephrine: An all-atom molecular dynamics study. *Phys. Chem. Chem. Phys.* **2022**, *24*, 20454–20465. [CrossRef]
132. Kumar, H.; Udgaonkar, J.B. Elongation of Fibrils Formed by a Tau Fragment is Inhibited by a Transient Dimeric Intermediate. J. Phys. Chem. B 2022, 126, 3385–3397. [CrossRef]  
133. Holmes, B.B.; Furman, J.L.; Mahan, T.E.; Yamasaki, T.R.; Mirbaha, H.; Eades, W.C.; Belaygorod, L.; Cairns, N.J.; Holtzman, D.M.; Diamond, M.I. Proteopathic tau seeding predicts tauopathy in vivo. Proc. Natl. Acad. Sci. USA 2014, 111, E4376–E4385. [CrossRef]  
134. Annadurai, N.; Malina, L.; Malohlava, J.; Hajdúch, M.; Das, V. Tau R2 and R3 are essential regions for tau aggregation, seeding and propagation. Biochimie 2020, 200, 79–86. [CrossRef]  
135. Hill, E.; Karikari, T.K.; Lantero-Rodriguez, J.; Zetterberg, H.; Blennow, K.; Richardson, M.J.; Wall, M.J. Truncating tau reveals different pathophysiological actions of oligomers in single neurons. Biochim Biophys Acta 2012, 1824, 348–357. [CrossRef]  
136. Tolar, M.; Hey, J.; Power, A.; Abushakra, S. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography. Neurobiol Aging 2022, 108, 106296. [CrossRef]  
137. Kim, Y.; Choi, H.; Lee, W.; Park, H.; Kam, T.-I.; Hong, S.-H.; Nah, J.; Jung, S.; Shin, B.; Lee, H.; et al. Caspase-cleaved tau exhibits rapid memory impairment associated with tau oligomers in a transgenic mouse model. Neurobiol Dis. 2016, 87, 19–28. [CrossRef]  
138. Lin, G.; Zhu, F.; Kanaan, N.M.; Asano, R.; Shirafuji, N.; Sasaki, H.; Yamaguchi, T.; Nomoto, S.; Endo, Y.; Ueno, A.; et al. Clioquinol Decreases Levels of Phosphorylated, Truncated, and Oligomerized Tau Protein. Int. J. Mol. Sci. 2021, 22, 12063. [CrossRef] [PubMed]  
139. Garg, S.; Timm, T.; Mandelkow, E.-M.; Mandelkow, E.; Wang, Y. Cleavage of Tau by calpain in Alzheimer’s disease: The quest for the toxic 17 kD fragment. Neurobiol Aging 2011, 32, 1–14. [CrossRef]  
140. Poelchau, M.; Mcbrayer, M.K.; Campbell, J.; Kumar, A.; Hashim, A.; Sershen, H.; Stavrides, P.H.; Ohno, M.; Hutton, M.; Nixon, R.A. Specific calpain inhibition by calpastatin prevents tauopathy and neurodegeneration and restores normal lifespan in tau F301L mice. J. Neurosci. 2014, 34, 9222–9234. [CrossRef]  
141. Zhang, Y.; Wu, K-M.; Yang, L.; Dong, Q.; Yu, J-T. Tauopathies: New perspectives and challenges. Mol. Neurodegener. 2022, 17, 28. [CrossRef]  
142. Wegmann, S.; Biernat, J.; Mandelkow, E. A current view on Tau protein phosphorylation in Alzheimer’s disease. Front. Mol. Neurosci. 2022, 15, 495753. [CrossRef] [PubMed]  
143. Iqbal, K.; Gong, C.X.; Liu, F. Hyperphosphorylation-induced tau oligomers. Front. Neurol. 2013, 4, 112. [CrossRef]  
144. Pradhan, A.; Mishra, S.; Surolia, A.; Panda, D. C1 Inhibits Liquid–Liquid Phase Separation and Oligomerization of Tau and Protects Neuroblastoma Cells against Toxic Tau Oligomers. ACS Chem. Neurosci. 2021, 12, 1989–2002. [CrossRef]  
145. Venkataramani, A.; Mukherjee, S.; Kumari, A.; Panda, D. Shikonin impedes phase separation and aggregation of tau and protects SH-SY5Y cells from the toxic effects of tau oligomers. Int. J. Biol. Macromol. 2022, 204, 19–33. [CrossRef] [PubMed]  
146. Ash, P.A.; Lei, S.; Shattuck, J.; Boudeau, S.; Carlonagno, Y.; Medalla, M.; Mashimo, B.L.; Soccoro, G.; Al-Mohanna, L.F.A.; Jiang, L.; et al. TTAI potentiates tau phase separation and promotes generation of toxic oligomeric tau. Proc. Natl. Acad. Sci. USA 2021, 118, e2014188118. [CrossRef] [PubMed]  
147. Martini, A.; Flach, M.; Springer, F.; Frank, S.; Tolnay, M.; Winkler, D.T. Severe oligomeric tau toxicity can be reversed without long-term sequelae. Brain 2021, 144, 963–974. [CrossRef] [PubMed]  
148. Cowan, C.M.; Quraishe, S.; Hands, S.; Sealey, M.; Mahajan, S.; Allan, D.W.; Mudher, A. Rescue from tau-induced neuronal dysfunction produces insoluble tau oligomers. Sci. Rep. 2015, 5, 17191. [CrossRef] [PubMed]  
149. Gyparaki, M.T.; Arab, A.; Sorokina, E.M.; Santiago-Ruiz, A.N.; Bohrer, C.H.; Xiang, J.; Lakadamyali, M. tau forms oligomeric complexes on microtubules that are distinct from tau aggregates. Proc. Natl. Acad. Sci. USA 2021, 118, e2021461118. [CrossRef]  
150. Kulenkampff, K.; Wolf Perez, A.-M.; Sormanni, P.; Habchi, J.; Vendruscolo, M. Quantifying misfolded protein oligomers as drug targets and biomarkers in Alzheimer and Parkinson diseases. Nat. Rev. Chem. 2021, 5, 277–294. [CrossRef]  
151. Vagenknecht, P.; Luzgin, A.; Ono, M.; Ji, B.; Higuchi, M.; Noain, D.; Maschio, C.A.; Sobek, J.; Chen, Z.; Konietzko, U.; et al. Non-invasive imaging of tau-targeted probe uptake by whole brain multi-spectral optoacoustic tomography. Eur. J. Nucl. Med. Mol. Imaging 2022, 49, 2137–2152. [CrossRef]  
152. Ayubcha, C.; Rigney, G.; Borja, A.J.; Werner, T.; Alavi, A. Tau-PET imaging as a molecular modality for Alzheimer’s disease. Am. J. Nucl. Med. Mol. Imaging 2021, 11, 374–386. [CrossRef]  
153. Maschio, C.; Ni, R. Amyloid and Tau Positron Emission Tomography Imaging in Alzheimer’s Disease and Other Tauopathies. Front. Aging Neurosci. 2022, 14, 383034. [CrossRef]  
154. Ni, R. Magnetic Resonance Imaging in Tauopathy Animal Models. Front. Aging Neurosci. 2022, 13, 791679. [CrossRef]  
155. Badachhapa, A.; Parekh, P.A.; Mu, Q.; Bhavane, R.; Srivastava, M.; Supin, I.; Bhandari, P.; Devkota, L.; Tanium, E.; Ghagbha, K.; et al. A novel MRI contrast agent for identifying hyperphosphorylative neurons as a marker of future tau pathology. Alzheimer’s Dement. 2020, 16, e041080. [CrossRef]  
156. Tolar, M.; Hey, J.; Power, A.; Abushakra, S. Neurotoxic Soluble Amyloid Oligomers Drive Alzheimer’s Pathogenesis and Represent a Clinically Validated Target for Slowing Disease Progression. Int. J. Mol. Sci. 2021, 22, 6355. [CrossRef] [PubMed]  
157. Arora, H.; Ramesh, M.; Rajasekhar, K.; Govindaraju, T. Molecular Tools to Detect Alloforms of Aβ and Tau: Implications for Multiplexing and Multimodal Diagnosis of Alzheimer’s Disease. Bull. Chem. Soc. Jpn. 2020, 93, 507–546. [CrossRef]  
158. Hansson, O.; Mormino, E.C. Is longitudinal tau PET ready for use in Alzheimer’s disease clinical trials? Brain 2018, 141, 1241–1244. [CrossRef]  
159. Zhao, Y.; Tietz, O.; Kuan, W.-L.; Haji-Dheere, A.K.; Thompson, S.; Vallin, B.; Ronchi, E.; Toth, G.; Klenerman, D.; Aigbirhio, F.I. A fluorescent molecular imaging probe with selectivity for soluble tau aggregated protein. Chem. Sci. 2020, 11, 4773–4778. [CrossRef]